Sold as Loxitane C, Loxitane Im. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Loxapine Hydrochloride (sold as Loxitane C, Loxitane Im), first approved May 4, 1976, with 0 new uses approved and 0 published complete response letters.
| May 4, 1976 | Loxitane CNDA 17658 · New active ingredient | Teva Branded Pharm | 28 | Discontinued |
| Oct 26, 1979 | Loxitane ImNDA 18039 · New dosage form | Actavis Labs Ut Inc | 14 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
